Progress in developing virus-like particle influenza vaccines

Quan, Fu‐Shi; Lee, Young-Tae; Kim, Ki-Hye; Kim, Min‐Chul; Kang, Sang-Moo

doi:10.1080/14760584.2016.1175942

Cited by 51 publications

(44 citation statements)

References 90 publications

(117 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VLP technology allows for the safe production of influenza vaccines containing one or more surface glycoproteins stabilized by the matrix (M1) assembly protein (Kang et al, 2009; Pushko et al, 2010; Quan et al, 2016). Our approach in this study was to generate VLP vaccines expressing NA, without homologous HA, and compare the protection efficacy conferred by a conventional HA-based VLP vaccine expressing homologous A/Indonesia/05/2005 HA protein.…”

Section: Discussionmentioning

confidence: 99%

Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets

et al. 2017

View full text Add to dashboard Cite

Avian influenza A (H5N1) viruses represent a growing threat for an influenza pandemic. The presence of widespread avian influenza virus infections further emphasizes the need for vaccine strategies for control of prepandemic H5N1 and other avian influenza subtypes. Influenza neuraminidase (NA) vaccines represent a potential strategy for improving vaccines against avian influenza H5N1 viruses. To evaluate a strategy for NA vaccination, we generated a recombinant influenza virus-like particle (VLP) vaccine comprised of the NA protein of A/Indonesia/05/2005 (H5N1) virus. Ferrets vaccinated with influenza N1 NA VLPs elicited high-titer serum NA-inhibition (NI) antibody titers and were protected from lethal challenge with A/Indonesia/05/2005 virus. Moreover, N1-immune ferrets shed less infectious virus than similarly challenged control animals. In contrast, ferrets administered control N2 NA VLPs were not protected against H5N1 virus challenge. These results provide support for continued development of NA-based vaccines against influenza H5N1 viruses.

show abstract

Section: Discussionmentioning

confidence: 99%

Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Since they lack genetic material, VLPs are not infectious nor replicative, making them safer alternatives to killed or attenuated virus [11] and have been long established for hepatitis B virus and human papillomavirus [12,13]. Several platforms, including VLPs, are under development as candidates for both seasonal and pandemic Influenza virus [9,10,[14][15][16][17].…”

mentioning

confidence: 99%

Universal label‐free in‐process quantification of influenza virus‐like particles

Carvalho

Moleirinho

Wheatley

et al. 2017

Biotechnology Journal

View full text Add to dashboard Cite

Virus‐like particles (VLPs) are becoming established as vaccines, in particular for influenza pandemics, increasing the interest in the development of VLPs manufacturing bioprocess. However, for complex VLPs, the analytical tools used for quantification are not yet able to keep up with the bioprocess progress. Currently, quantification for Influenza relies on traditional methods: hemagglutination assay or Single Radial Immunodiffusion. These analytical technologies are time‐consuming, cumbersome, and not supportive of efficient downstream process development and monitoring. Hereby we report a label‐free tool that uses Biolayer interferometry (BLI) technology applied on an Octet platform to quantify Influenza VLPs at all stages of bioprocess. Human (α2,6‐linked sialic acid) and avian (α2,3‐linked sialic acid) biotinylated receptors associated with streptavidin biosensors were used, to quantify hemagglutinin content in several mono‐ and multivalent Influenza VLPs. The applied method was able to quantify hemagglutinin from crude samples up to final bioprocessing VLP product. BLI technology confirmed its value as a high throughput analytical tool with high sensitivity and improved detection limits compared to traditional methods. This simple and fast method allowed for real‐time results, which are crucial for in‐line monitoring of downstream processing, improving process development, control and optimization.

show abstract

“…An influenza pandemic is an outbreak of a novel influenza virus that can spread worldwide. During the 2009 influenza pandemic, we observed significant shortages and delays of egg-based vaccines in the global supply [5]. Technology of non-replicating VLPs represents an alternative option since it is immunogenic, safe, and [57].…”

Section: Influenza Vlp Vaccine Against Potential Pandemic Influenza Vmentioning

confidence: 99%

“…According to the report of World Health Organization, every year 250,000 to 500,000 deaths occur due to the infection of influenza virus [4]. Different platforms for influenza vaccines have been available on the market, such as inactivated split vaccine, live attenuated influenza vaccines (LAIV) and recombinant purified subunit protein vaccines [5,6].…”

Section: Introductionmentioning

confidence: 99%

Progress in the development of virus-like particle vaccines against respiratory viruses

Quan

Basak

Chu

et al. 2020

Expert Review of Vaccines

Self Cite

View full text Add to dashboard Cite

Introduction: Influenza virus, human respiratory syncytial virus (RSV), and human metapneumovirus (HMPV) are important human respiratory pathogens. Recombinant virus-like particle (VLP) vaccines are suggested to be potential promising platforms to protect against these respiratory viruses. This review updates important progress in the development of VLP vaccines against respiratory viruses. Areas Covered: This review summarizes progress in developing VLP and nanoparticle-based vaccines against influenza virus, RSV, and HMPV. The PubMed was mainly used to search for important research articles published since 2010 although earlier key articles were also referenced. The research area covered includes VLP and nanoparticle platform vaccines against seasonal, pandemic, and avian influenza viruses as well as RSV and HMPV respiratory viruses. The production methods, immunogenic properties, and vaccine efficacy of respiratory VLP vaccines in preclinical animal models and clinical studies were reviewed in this article. Expert opinion: Previous and current preclinical and clinical studies suggest that recombinant VLP and nanoparticle vaccines are expected to be developed as promising alternative platforms against respiratory viruses in future. Therefore, continued research efforts are warranted. ARTICLE HISTORY

show abstract

Progress in developing virus-like particle influenza vaccines

Cited by 51 publications

References 90 publications

Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets

Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets

Universal label‐free in‐process quantification of influenza virus‐like particles

Progress in the development of virus-like particle vaccines against respiratory viruses

Contact Info

Product

Resources

About